Skip to search formSkip to main contentSkip to account menu

BN83495

Known as: Steroid Sulfatase Inhibitor BN 83495 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

irosustat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
A Phase II Multicenter Randomized Open-Label Study of Oral Steroid Sulphatase (STS) Inhibitor Irosustat (BN83495) Versus Megestrol Acetate (MA) in Women with Advanced/Recurrent Endometrial Cancer (EC…
2009
2009
A Phase I Dose Escalation Study of Steroid Sulfatase Inhibitor BN83495/STX64 in Postmenopausal Women with ER Positive Breast Cancer.
Background: BN83495/STX64 is an irreversible steroid sulfatase (STS) inhibitor blocking the hydrolysis of sulfated estrone E1S… 
2008
2008
Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.
Steroid sulphatase (STS) inhibitors have been developed primarily for the treatment of hormone-dependent breast cancer, but may… 
2008
2008
163 POSTER The steroid sulfatase inhibitor BN83495 inhibits E1S-stimulated growth of DMBA-induced mammary tumour in rat
Review
2007
Review
2007
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Inhibitors of steroid sulfatase are being developed as a novel therapy for hormone-dependent breast cancer in postmenopausal… 
2007
2007
Discovery and development of sulfatase inhibitors via academia, biotech & mid-size pharma
SY25-01 Breast cancer remains a major cause of death in women in most Western countries. While estrogens have an important role… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)